Despite a significant lag behind the broader market over the past year, analysts maintain a cautiously optimistic stance on Copart's long-term prospects, even as near-term headwinds persist.
Despite OPEC+ maintaining production cuts, crude benchmarks fell sharply on Monday, pulling energy stocks like ConocoPhillips down with them as immediate fears of a supply disruption in the Persian Gulf subsided.
A Barcelona hospital has completed a groundbreaking facial transplant, the first of its kind globally where the donor offered her face as part of an assisted dying process. The recipient, who lost facial function to a severe infection, is now recovering well.
Indonesian authorities have conditionally lifted the ban on the Grok AI chatbot after receiving a detailed compliance plan from X Corp. The move follows regional concerns over the platform's misuse for generating explicit deepfakes.
The investment fund sold $3.87 million worth of shares in the Argentine bank, reflecting a strategic portfolio adjustment as the lender navigates a challenging economic environment.
AIGH Capital Management has liquidated its entire position in semiconductor firm MaxLinear, a move that coincides with the chipmaker's recent strong quarterly earnings report, raising questions about the fund's strategy.
The CoinDesk 20 Index, a key benchmark for the digital asset market, fell sharply over the weekend, with every constituent in the red. Ethereum's 13.9% drop was a primary driver of the downturn.
With one in twelve salaried employees having worked in multiple countries, Colgate-Palmolive is leveraging international assignments as a core strategy to build agile, globally-minded leadership.
Meta Platforms' relentless investment in artificial intelligence infrastructure is set to drive capital expenditures to unprecedented levels in 2026, raising questions about long-term returns for the cash-rich tech giant.
Shares of Coastal Financial (CCB) have retreated sharply from recent highs, reigniting the debate over the fintech-focused bank's premium valuation. While long-term performance remains strong, current momentum is fading, leaving investors to weigh high growth expectations against traditional valuation metrics.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
As economic pressures mount, flexible remote work opportunities are evolving. We examine four proven side gigs that experts project can still generate significant weekly earnings from home in the coming years.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
The International Monetary Fund projects average growth in sub-Saharan Africa at 4.6% for the year, edging ahead of Asia's 4.1%, signaling a potential turning point driven by demographics but tempered by significant investment challenges.
Ford Motor Company launches a dedicated energy storage business, Ford Energy, appointing Lisa Drake to lead the charge into the rapidly growing battery storage market, signaling a strategic expansion beyond vehicle manufacturing.
A sharp weekend correction saw Bitcoin tumble over 7%, erasing billions in leveraged positions. While the immediate trigger appears tied to political uncertainty, analysts point to overheated market conditions as the deeper cause, even as institutional sentiment remains cautiously optimistic.
Investment firm Curreen Capital, known for targeting undervalued 'ugly duckling' companies, highlighted contract research organization Fortrea Holdings as a prime example of its strategy in its latest investor letter. The firm reported a 30.97% return for 2025.
Investors in lighting specialist FW Thorpe have seen a negative total shareholder return of 25% since 2021, starkly underperforming the broader market's gains. Despite steady revenue growth, the share price decline highlights a disconnect with company fundamentals.
